Microbot Medical Inc. announced the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. The study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endov vascular Robotic Surgical System.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.949 USD | +2.31% | -0.40% | -42.13% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.13% | 13.36M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study